Erythrocytic α-Synuclein Species for Parkinson's Disease Diagnosis and the Correlations With Clinical Characteristics

Overview

Journal Front Aging Neurosci

Specialty Geriatrics

Date 2022 Feb 21

PMID 35185529

Authors

Zhenwei Yu

Genliang Liu

Yang Li

Ehsan Arkin

Yuanchu Zheng

Tao Feng

Affiliations

Soon will be listed here.

Abstract

Background: Erythrocytes contain most of the peripheral α-synuclein (α-syn), which is the key pathological molecular of α-synucleinopathies including Parkinson's disease (PD). Our objectives were to assess the efficiency of erythrocytic total and oligomeric α-syn levels as PD diagnostic biomarkers, and to identify the correlations between erythrocytic α-syn levels and physiological/psychiatrical assessment scales.

Methods: Home-brewed electrochemiluminescence assays were applied to assess the concentrations of erythrocytic total and oligomeric α-syn levels in a cohort including 124 patients with PD and 79 healthy controls (HCs). The correlations between erythrocytic α-syn levels and clinical measurements were assessed using Spearman's rank test.

Results: Both the erythrocytic total and oligomeric α-syn levels were significantly higher in PD patients than HCs. The biomarkers adjusted for age and sex discriminated PDs from HCs well with 80% sensitivity, 89% specificity and 79% sensitivity, 83% specificity, respectively. Combining erythrocytic total and oligomeric α-syn levels by using binary logistic regression analysis with the controlling of age and sex generated a factor discriminates PDs from HCs with 88% sensitivity and 85% specificity. The erythrocytic total but not oligomeric α-syn levels adjusted for age and sex significantly correlated with anxiety scales and the MDS-UPDRS III scales in PD patients, respectively.

Conclusion: We showed the usefulness of erythrocytic total and oligomeric α-syn levels as biomarkers for PD. Our results also suggest the capability of erythrocytic α-syn as a potential pathological factor and therapeutic target for psychiatric symptoms in PD patients.

Citing Articles

Differences in Blood and Cerebrospinal Fluid Between Parkinson's Disease and Related Diseases.

Ma J, Tang Z, Wu Y, Zhang J, Wu Z, Huang L Cell Mol Neurobiol. 2024; 45(1):9.

PMID: 39729132 PMC: 11680620. DOI: 10.1007/s10571-024-01523-z.

Erythrocytic α-Synuclein in Parkinson's Disease and Progressive Supranuclear Palsy-A Pilot Study.

Cristiani C, Scaramuzzino L, Parrotta E, Cuda G, Quattrone A, Quattrone A Biomedicines. 2024; 12(11).

PMID: 39595076 PMC: 11592387. DOI: 10.3390/biomedicines12112510.

Structural basis of epitope recognition by anti-alpha-synuclein antibodies MJFR14-6-4-2.

Lieknina I, Reimer L, Pantelejevs T, Lends A, Jaudzems K, El-Turabi A NPJ Parkinsons Dis. 2024; 10(1):206.

PMID: 39463404 PMC: 11514253. DOI: 10.1038/s41531-024-00822-y.

Correlations of erythrocytic oligomer α-synuclein levels with age, sex and clinical variables in patients with Parkinson's disease.

Lu Z, Yu X, Li P, Wang Y, Deng Y, Li X Front Aging Neurosci. 2024; 16:1437622.

PMID: 39144258 PMC: 11322579. DOI: 10.3389/fnagi.2024.1437622.

Aggregation-resistant alpha-synuclein tetramers are reduced in the blood of Parkinson's patients.

De Boni L, Wallis A, Watson A, Ruiz-Riquelme A, Leyland L, Bourinaris T EMBO Mol Med. 2024; 16(7):1657-1674.

PMID: 38839930 PMC: 11250827. DOI: 10.1038/s44321-024-00083-5.

References

Mollenhauer B, Cullen V, Kahn I, Krastins B, Outeiro T, Pepivani I . Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol. 2008; 213(2):315-25. DOI: 10.1016/j.expneurol.2008.06.004. View

Piredda R, Desmarais P, Masellis M, Gasca-Salas C . Cognitive and psychiatric symptoms in genetically determined Parkinson's disease: a systematic review. Eur J Neurol. 2019; 27(2):229-234. DOI: 10.1111/ene.14115. View

Reijnders J, Ehrt U, Weber W, Aarsland D, Leentjens A . A systematic review of prevalence studies of depression in Parkinson's disease. Mov Disord. 2007; 23(2):183-9. DOI: 10.1002/mds.21803. View

Shi M, Zabetian C, Hancock A, Ginghina C, Hong Z, Yearout D . Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease. Neurosci Lett. 2010; 480(1):78-82. PMC: 2943649. DOI: 10.1016/j.neulet.2010.06.009. View

Bruno D, Reichert Plaska C, Clark D, Zetterberg H, Blennow K, Verbeek M . CSF α-synuclein correlates with CSF neurogranin in late-life depression. Int J Neurosci. 2020; 131(4):357-361. PMC: 7529713. DOI: 10.1080/00207454.2020.1744596. View

Hong Z, Shi M, Chung K, Quinn J, Peskind E, Galasko D . DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain. 2010; 133(Pt 3):713-26. PMC: 2842513. DOI: 10.1093/brain/awq008. View

El-Agnaf O, Salem S, Paleologou K, Curran M, Gibson M, Court J . Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J. 2006; 20(3):419-25. DOI: 10.1096/fj.03-1449com. View

Matsumoto J, Stewart T, Sheng L, Li N, Bullock K, Song N . Transmission of α-synuclein-containing erythrocyte-derived extracellular vesicles across the blood-brain barrier via adsorptive mediated transcytosis: another mechanism for initiation and progression of Parkinson's disease?. Acta Neuropathol Commun. 2017; 5(1):71. PMC: 5598000. DOI: 10.1186/s40478-017-0470-4. View

Tokuda T, Qureshi M, Ardah M, Varghese S, Shehab S, Kasai T . Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease. Neurology. 2010; 75(20):1766-72. DOI: 10.1212/WNL.0b013e3181fd613b. View

10.

Kano O, Ikeda K, Cridebring D, Takazawa T, Yoshii Y, Iwasaki Y . Neurobiology of depression and anxiety in Parkinson's disease. Parkinsons Dis. 2011; 2011:143547. PMC: 3109308. DOI: 10.4061/2011/143547. View

11.

Fan J, Chang B, Wu Y . Relationships among Depression, Anxiety, Sleep, and Quality of Life in Patients with Parkinson's Disease in Taiwan. Parkinsons Dis. 2016; 2016:4040185. PMC: 4884599. DOI: 10.1155/2016/4040185. View

12.

Shi M, Bradner J, Hancock A, Chung K, Quinn J, Peskind E . Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol. 2011; 69(3):570-80. PMC: 3117674. DOI: 10.1002/ana.22311. View

13.

Fanciulli A, Stankovic I, Krismer F, Seppi K, Levin J, Wenning G . Multiple system atrophy. Int Rev Neurobiol. 2019; 149:137-192. DOI: 10.1016/bs.irn.2019.10.004. View

14.

Schrag A . Quality of life and depression in Parkinson's disease. J Neurol Sci. 2006; 248(1-2):151-7. DOI: 10.1016/j.jns.2006.05.030. View

15.

Upneja A, Paul B, Jain D, Choudhary R, Paul G . Anxiety in Parkinson's Disease: Correlation with Depression and Quality of Life. J Neurosci Rural Pract. 2021; 12(2):323-328. PMC: 8110433. DOI: 10.1055/s-0041-1722840. View

16.

Kalia L, Lang A . Parkinson's disease. Lancet. 2015; 386(9996):896-912. DOI: 10.1016/S0140-6736(14)61393-3. View

17.

Tian C, Liu G, Gao L, Soltys D, Pan C, Stewart T . Erythrocytic α-Synuclein as a potential biomarker for Parkinson's disease. Transl Neurodegener. 2019; 8:15. PMC: 6521422. DOI: 10.1186/s40035-019-0155-y. View

18.

Postuma R, Berg D, Stern M, Poewe W, Olanow C, Oertel W . MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord. 2015; 30(12):1591-601. DOI: 10.1002/mds.26424. View

19.

Majbour N, Vaikath N, van Dijk K, Ardah M, Varghese S, Vesterager L . Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson's disease. Mol Neurodegener. 2016; 11:7. PMC: 4717559. DOI: 10.1186/s13024-016-0072-9. View

20.

Pretorius E, Swanepoel A, Buys A, Vermeulen N, Duim W, Kell D . Eryptosis as a marker of Parkinson's disease. Aging (Albany NY). 2014; 6(10):788-819. PMC: 4247384. DOI: 10.18632/aging.100695. View